Cayman Chemical, a leading supplier of high-quality lipids and tools for lipid nanoparticle (LNP) research and development, and Certest Pharma, a biotechnology company focused on infectious disease and advanced nucleic acid-based therapies, announced a new partnership to make Certest proprietary ionizable lipids available for LNP research through Cayman’s online catalog and global network of distributors.
Certest’s library of proprietary lipids offers researchers expanded opportunities to develop effective and targeted LNPs. These lipids outperformed existing ionizable lipids, demonstrating superior immune stimulation and eliciting stronger responses. The library also includes lipids that have been tailored for specific applications like targeted organ delivery or high protein expression.
Through the agreement, select Certest lipids will also be available for custom LNP development through Cayman’s LNP discovery formulation and screening services, and as CGMP lipid components for use in formulating LNP-based therapeutics. The partnership plans to continue expanding its ionizable lipid portfolio, providing researchers with more options for formulating LNPs.
Also Read: Crown Bioscience & CTI Collaborate on Oncology Drug Consulting
Sebastian Buchert, Cayman Vice President of Sales and Marketing states, “our partnership with Certest is a great fit to strengthen Cayman’s position as a total solution provider in the LNP space, expanding our curated platform of biochemicals and LipidLaunch™ research tools. Whether formulating themselves or through our contract services experts, Certest novel ionizable lipids will help researchers around the world improve LNP formulations, expand applications, and innovate in the rapidly emerging field of lipid-based drug delivery.”
Nelson Fernandes, CEO of Certest, remarked, “Cayman has been a leader in lipid research for over forty years, their global footprint and trusted brand made it a logical fit to swiftly bring Certest lipids into the hands of researchers worldwide through a reliable source. Our characterized lipids stand to advance therapeutic approaches to vaccination, gene delivery, and gene editing strategies by offering improved performance over benchmark standard formulations.”
Researchers that identify a Certest lipid as a component in their LNP screening formulations can secure licensing for clinical investigation and commercial use through Certest and CGMP lipid supply from Cayman’s US-based CGMP manufacturing facilities in Ann Arbor, Michigan. These lipids are licensable from Certest, offering cost-effective, premium ionizable cationic lipids with freedom to operate outside of existing patent-protected LNP formulations.
SOURCE: PRWeb